Anthem Biosciences IPO lists today, July 21. Check latest GMP, listing price prediction, market debut updates, and investor outlook for the new stock.
Anthem Biosciences IPO Listing Today: Will Shares Soar Over 30% on Debut?
Mumbai, July 21, 2025 — All eyes are on Anthem Biosciences as it debuts on the BSE and NSE today, following an overwhelming IPO response. The company, a leader in fermentation-based APIs, drew significant interest from both institutional and retail investors. With the grey market premium (GMP) suggesting a listing price of nearly ₹750—a potential 31% gain over its issue price—investors are eagerly awaiting the stock’s first tick at 10:00 AM during the Special Pre-open Session (SPOS).
📌 Anthem Biosciences IPO: Key Highlights
- IPO Opened: July 14, 2025
- IPO Closed: July 16, 2025
- Price Band: ₹560 – ₹570 per share
- Final Issue Price: ₹570 per share
- IPO Size: ₹1,500 crore
- Allotment Date: July 17, 2025
- Listing Date: Today, July 21, 2025
- Stock Exchange: BSE & NSE
- Grey Market Premium (GMP): ₹179 (as of 8:22 AM, July 21)
💹 IPO Subscription Details: Massive Oversubscription
The IPO received an overall subscription of 67.42 times, reflecting strong investor confidence in the company’s business fundamentals and growth prospects.
Subscription Breakdown:
- Qualified Institutional Buyers (QIBs): 192.80x
- Non-Institutional Investors (NIIs): 44.70x
- Retail Individual Investors (RIIs): 5.98x
Such heavy bidding, especially by QIBs, is a bullish indicator for the stock’s performance in secondary markets.
🔍 Anthem Biosciences IPO GMP Today: Strong Signals
The grey market premium (GMP) for Anthem Biosciences IPO stands at ₹179 per share as of July 21 morning. With the IPO price at ₹570, the expected listing price is ₹749, reflecting an estimated listing gain of 31.40%.
Expert Commentary:
“Anthem Biosciences is likely to list between ₹700 and ₹750 per share. The strong institutional demand and high GMP signal a premium debut,”
— Mahesh M. Ojha, AVP – Research & Business Development, Hensex Securities.
He added that the company’s fundamentals justify the valuation, and a solid listing would reflect market optimism for biosciences and CRAMS-based businesses.
🧪 About Anthem Biosciences: Company Overview
Anthem Biosciences is a leading CRAMS (Contract Research and Manufacturing Services) company specializing in fermentation-based active pharmaceutical ingredients (APIs). The company supports global pharma, biotech, and specialty chemical clients with R&D and manufacturing services.
Key Strengths:
- State-of-the-art research infrastructure
- High-margin fermentation segment
- Long-term contracts with global pharmaceutical giants
- Robust pipeline and diversification plans
With growing demand for high-quality API production, Anthem is well-positioned in a thriving industry.
📈 Listing Strategy: What Should Investors Do?
Analysts are optimistic, but advise profit-booking on listing gains for short-term investors, while long-term investors may consider holding due to the company’s growth trajectory and strong order book.
Listing Strategy by Investor Type:
- Short-Term Traders: Consider partial profit booking if the stock lists above ₹730
- Long-Term Investors: Hold and watch quarterly results and post-IPO expansion updates
- New Entrants: Wait for post-listing price stability before entering
📊 Financial Performance Snapshot (FY24)
| Metric | Value |
|---|---|
| Revenue | ₹845 crore |
| EBITDA Margin | 22.8% |
| Net Profit | ₹152 crore |
| ROCE | 18.5% |
| Debt-to-Equity | 0.42 |
Strong profitability, efficient capital utilization, and a lean balance sheet add to investor confidence.
❓ FAQs on Anthem Biosciences IPO Listing
1. What is the listing date of Anthem Biosciences IPO?
Anthem Biosciences shares will be listed today, July 21, 2025, on both the BSE and NSE.
2. What is the latest GMP of the Anthem Biosciences IPO?
The latest grey market premium (GMP) is ₹179 per share, indicating a possible listing price around ₹749.
3. What was the IPO issue price of Anthem Biosciences?
The IPO was priced at ₹570 per share.
4. How much was the IPO subscribed?
The IPO was oversubscribed 67.42 times, with QIBs subscribing 192.80x.
5. Should I buy Anthem Biosciences shares on listing?
Analysts suggest waiting for post-listing price action for fresh entry. Short-term investors may book profits if listed above expectations.
BSE India Listing Notice for Anthem Biosciences – Official exchange confirmation on listing and trading group.
🗣️ Final Verdict: Strong Debut on the Cards
Given the overwhelming investor interest, high GMP, and strong financials, Anthem Biosciences is likely to deliver a robust debut. If the stock lists around ₹749 as expected, investors can lock in healthy gains of over 30%. However, market volatility and listing-day sentiment can impact the outcome.
✅ Call to Action (CTA)
What are your views on Anthem Biosciences’ IPO listing? 📈
💬 Comment below, 🔁 share this with fellow investors, and 👉 follow QuickNews.Press for real-time IPO coverage and stock market updates.
